(The Defender)—People who take the popular weight-loss drugs like Ozempic and Wegovy are 45% more likely to have suicidal thoughts than people taking other drugs, according to a study published Tuesday in the Journal of the American Medical Association (JAMA).
Researchers from the Zucker School of Medicine in New York reviewed a World Health Organization global database of adverse drug effects between November 2000 and August 2023.
They compared reporting rates for semaglutide — the active ingredient in the blockbuster drugs — to other similar weight-loss drugs and all drugs in the database. They found that semaglutide was associated with “disproportionately increased reporting of suicidality.”
“Authorities should consider issuing a warning to inform about this risk,” the authors concluded, particularly given the increasing off-label use of the drug. They said in half of the cases where suicidal thoughts occurred, the drug was being taken off-label.
The signal “warrants urgent clarification,” they added.
The researchers also found a higher risk for suicidal thoughts among people on antidepressants or benzodiazepines, likely prescribed for depression or anxiety, who were also taking semaglutide.
They recommended that physicians who prescribe semaglutide inform patients of the risk and assess their psychiatric history and mental state before prescribing the drug.
‘If you want to check if a drug causes suicidality, you have to interview people’
In more than half of the cases the researchers studied, suicidal thoughts stopped when people stopped taking the drugs.
Dr. David Healy, a psychiatrist who was not involved in the study, told The Defender this was one of the more significant findings. The overall number of suicidal thoughts reported was small, he said, but the proportion of cases where the thoughts stopped when the drug was stopped was high.
This is telling, he said. However, he said investigations must happen at the clinical level to determine causality. “If you want to check if a drug causes suicidality — you have to interview people,” he said.
The researchers also found a slight increase in reports of suicidal ideation in the database for the earlier version of the weight loss medication, liraglutide — sold under the brand name Victoza and Saxenda.
Liraglutide is in the same broader class of glucagon-like peptide-1 (GLP-1) receptor agonist drugs as semaglutide.
Accompanying commentary by authors Francesco Salvo, M.D., Ph.D., of the Université de Bordeaux and Jean-Luc Faillie, M.D., Ph.D., of the Université de Montpellier in France, affirmed that GLP-1 receptor agonists should be prescribed with “great caution in patients with a history of depression or suicidal attempts.”
They added that the drug should be discontinued if new depression symptoms occur when on the drugs.
FDA and EMA claim no evidence of link
The injectable prescription drugs were originally developed to manage blood sugar levels in the treatment of Type 2 diabetes, but they became wildly popular over the last several years for their ability to help people lose weight.
GLP-1 receptor agonists are chemicals derived from lizard venom that can change people’s metabolism and eating behaviors as long as they continue to take the drugs.
When people stop taking the drugs, they typically regain most or all of the weight they lost.
The drugs have been touted by Oprah Winfrey and other celebrities as a key to overcoming the obesity epidemic.
Mainstream health publications like StatNews have advocated for increasing access to the expensive obesity drugs in the name of racial justice, and there has been growing pressure for the drugs to be covered without restrictions by Medicare.
And medical organizations like the American Academy of Pediatrics rushed to recommend the drugs for children as young as 8, just weeks after they were approved by the U.S. Food and Drug Administration (FDA) for children.
And in October 2023, Novo Nordisk announced that it is testing semaglutide in children as young as 6.
The drugs are new to the market. Novo Nordisk, the Danish pharmaceutical company that makes Ozempic, Wegovy and Saxenda only published its clinical trial showing weight loss effects of semaglutide in February of 2021 and the FDA approved Wegovy for weight loss in June 2021.
Between 2020 and 2023, GLP-1 receptor agonists use increased by 594% in young people, particularly among women.
Despite the hype, serious concerns have been raised about the safety of the drugs. They’ve been linked to cancers in the digestive system, thyroid cancer, stomach paralysis, a wide range of other gastrointestinal disorders, among other issues and the drugs pose a serious but little-known risk for pregnant women.
Last year, suicidal ideation linked to Ozempic and Saxenda, and one case of self-harm ideation linked to Saxenda were reported in Iceland, which led to an investigation by the European Medicines Agency (EMA). Similar reports were also made to the FDA.
The EMA reported in April that its follow-up investigation, which reviewed non-clinical studies, clinical trials and postmarketing surveillance data, “does not support a causal association” between GLP-1 drugs and suicidal or self-harm thoughts.
The FDA reported in January that its investigation of reports to the FDA Adverse Event Reporting System (FAERS) showed no safety signal for the drugs and that it had a meta-analysis underway.
A study published in Nature in January found no link between the drugs and suicidal thoughts
The EMA continues to maintain that no warning is warranted, but in U.S. labeling, the product information for semaglutide does list thoughts of suicide as a possible side effect.
Novo flagged “several limitations” of the new study and maintained that it will continue to work with the FDA and other regulators to monitor the safety of the drugs, Fierce Pharma reported.
“We stand behind the safety and efficacy of all of our GLP-1RA medicines when they are used as indicated and when taken under the care of a licensed healthcare professional,” the spokesperson said. “The known risks associated with use of these medicines are reflected in their current FDA- and EMA-approved product labeling.”
Suicidal thoughts and suicides occurred in clinical trials
Despite the EMA and FDA’s continued claims of safety for GLP-1 agonists, in the clinical trials for liraglutide there was a higher incidence of suicidal thoughts versus the placebo, although the number was not statistically significant, the Japanese journal MedCheck reported in its overview of the drug, recommending against its use.
In another liraglutide trial, reported in the New England Journal of Medicine, of 125 trial participants, there were three reported suicidal cases — two attempted and one completed suicide. The suicide was judged by the clinicians not to be related to the drug.
In its reporting to the FDA for Wegovy approval, Novo Nordisk also reported a slightly higher rate of suicide, which they said was not statistically significant, among participants in the semaglutide group.
They also reported four fatal events of suicide — one serious attempt and three completed suicides — in blinded data. Because the data were blinded, they reported that it could not be assessed whether the suicides were linked to the drugs.
Some argue that obese people have a mental illness that leads to an increased risk of suicidal ideation, but research doesn’t support that theory. One recent study showed that obese men in the U.S. actually have lower rates of suicidal ideation.
The issue of suicidal thoughts linked to weight-loss drugs has been a major hurdle to the drug industry’s ability to develop lucrative weight-loss drugs.
An earlier weight-loss drug — Sanofi’s Acomplia (rimonabant) — was pulled from European markets because it caused suicidal ideation. It never won approval in the U.S.
Diet pills Contrave by Currax Pharmaceuticals and Qsymia by Vivus, approved in the U.S. in 2014 and 2012, respectively, also carry warnings on their labels about the increased risk of suicidal thoughts.
Two Storms, One Harvest
Every food crisis in living memory has been a one-shock event. The 2008 price spike was a commodity bubble. The 2020 shortages were a logistics failure. The 2022 grain scare was a war on one exporter’s ports. Each time, the system bent, adjusted, and recovered, and each time the experts assured us afterward that global markets are simply too big and too diversified to fail.
What nobody in Washington seems eager to discuss is that 2026 is shaping up to be something the modern food system has never actually faced. Two independent shocks, one climatic and one geopolitical, are converging on the same harvest cycle at the same time. Not sequentially. Simultaneously.
Start with the weather. The Pacific Ocean is currently building toward what forecasters now openly call a record event. NOAA’s Climate Prediction Center puts the odds of at least a strong El Niño near 88 percent, with roughly two in three odds it reaches “very strong” status, the tier reserved for perhaps three or four events in the entire satellite era. Every major global model now projects a median peak in Super El Niño territory, and most of them project it exceeding the 2015-16 event, which until now held the modern record. Sea surface anomalies were already brushing the super threshold in mid-July, months before these events normally peak. The atmosphere has already shifted into El Niño mode, and the event is forecast to crest in late fall and early winter.
This is not about “climate change.” It’s about the standard cycles of weather, and the cycle we’re currently in is one that has likely devastated societies in the past. We’re better prepared as a society today, but not all Americans are equally prepared.
Serious households have started doing the quiet math on their own. Grocery bills tell part of the story, and the forecast maps tell the rest, which is why long-term food storage has moved from fringe hobby to mainstream line item in the family budget, with established suppliers like Heaven’s Harvest seeing demand from people who five years ago would have rolled their eyes at the idea. That instinct is not paranoia. It is pattern recognition, and the pattern is worth walking through carefully.
Editor’s Note: Heaven’s Harvest IS a sponsor, but the warnings of this article are real and would be written even if we didn’t have a survival food sponsor. With that said, those who take advantage of what they offer can use promo code “Patriot” for 15% off.
The Fertilizer Clock Is Already Running
While the Pacific warms, the second shock has been unfolding in the Strait of Hormuz. The conflict with Iran turned the world’s most important energy chokepoint into a contested waterway, and the consequences reach far beyond the gas pump. Roughly a third of global fertilizer trade moves through Hormuz, and the disruption sent urea prices up 86 percent year over year by March, with a 53 percent jump in a single month.
The World Bank projects energy prices rising about 24 percent in 2026 and fertilizer about 31 percent. By its own accounting, fertilizer prices ran 35 percent higher in the first five months of this year than the same period last year.
Here is the mechanism the nightly news will not explain. Fertilizer is not a grocery item. It is a time-delayed input. The nitrogen a farmer in Iowa or Punjab could not afford to apply this spring does not show up as a problem this spring. It shows up as a thinner harvest six to twelve months later.
The World Bank’s own food security brief concedes that the effects of reduced applications earlier this season “are likely to become visible only later in harvest outcomes.” Translate that from institutional language into plain English and it means this. The damage is already done, it is already in the ground, and we are simply waiting for it to arrive on the shelf.
Now check the calendar. Six to twelve months from the spring planting season lands us squarely in late 2026 and early 2027. Which is precisely when the strongest El Niño in the instrumental record is forecast to peak, bringing its signature droughts to Southeast Asia, Australia, southern Africa, northern Brazil, and South Asia, the very regions that grow the world’s rice, sugar, and oilseeds.
The World Bank warns openly that a strong El Niño “could disrupt multiple crop belts simultaneously” on top of the conflict-driven input costs. Their baseline projection assumes the Middle East disruptions ease by autumn. What in the last two years of Middle East history suggests that assumption is safe?
The System Has No Slack Left
The comfortable answer is that global markets always adjust. But adjustment requires slack, and the slack is gone. Global cereal production is expected to decline from last year’s records even before El Niño does its work. The UN World Food Programme, hardly a den of right-wing preppers, is calling this the most significant disruption to its supply chains since Covid and the invasion of Ukraine, and its supply chain director put the stakes bluntly.
Today’s supply chain challenges are tomorrow’s hunger crisis.
There is also a political dimension that markets cannot price. When food gets scarce, governments do not behave like economists. They behave like politicians. Export bans, hoarding mandates, and panic buying at the national level turned the modest rice shortfall of 2008 into a global crisis, and analysts are already warning that import-dependent nations are the first dominoes.
The 2015-16 Super El Niño, a far weaker event than what is now forecast, threw tens of millions into food stress across Africa and Asia. This one is projected to be stronger, and it arrives with fertilizer already rationed by price and shipping lanes already contested by missiles.
What Joseph Knew
Scripture does not treat preparation for lean years as faithlessness. It treats it as wisdom delivered in advance to those willing to act on it.
Behold, there come seven years of great plenty throughout all the land of Egypt: And there shall arise after them seven years of famine; and all the plenty shall be forgotten in the land of Egypt.
Joseph did not respond to that warning with a hashtag or a committee. He stored grain during the years of abundance, and when the famine came, Egypt stood while its neighbors begged. The lesson is not that famine is certain. It is that the time to prepare is precisely when preparation still looks optional.
Nobody who filled a pantry in a year of plenty has ever regretted it, and nobody standing in an empty aisle has ever been glad he waited for certainty.
None of this calls for panic, and panic is the enemy of sound judgment anyway. It calls for the same unglamorous prudence our grandparents considered ordinary. Keep some cash margin, know your local growers, and put real food in deep storage while it is cheap and available, because the entire arc of this story is that cheap and available is a closing window.
Families looking for a straightforward place to start can visit Heaven’s Harvest and use promo code Patriot for 15 percent off long-term storable food. The forecasts may yet soften, the strait may yet reopen, and we should pray they do. But hope is a fine thing to hold and a foolish thing to eat.
